Rafael Fonseca, Hematologist at Mayo Clinic, shared a post on X:
“Much higher rate of serious neuropathy for bortezomib vs carfilzomib. Most trials on left used biweekly but two, marked by asterisk, use weekly.
This plots only Gr3/4 (available trial data) but grade 2 is important, and even grade 1.”
Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment. He has led research on genetic markers in myeloma. Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.